Therapy News and Research

RSS

AskBio enters patent license agreement with Pfizer for HCV therapy

Asklepios BioPharmaceutical, Inc., a privately-owned clinical-stage biotechnology company, announced today it has entered into a patent license agreement with Pfizer, Inc. granting Pfizer access to certain proprietary gene-delivery platform technologies developed by AskBio, for use in developing novel therapies for patients with Hepatitis C virus (HCV).

14 Sep 2010

Repetitive transcranial magnetic stimulation helps to regain motor function in partially paralyzed patients

Stroke patients who were left partially paralysed found that their condition improved after they received a simple and non-invasive method of brain stimulation, according to research in the September issue of the European Journal of Neurology.

14 Sep 2010

St. John Hospital commences enrollment in CONNECT trial for peripheral artery disease

St. John Hospital and Medical Center in Detroit and Avinger, Inc., a medical device company focused on the development of innovative devices to combat peripheral artery disease, announced today the enrollment of the first patient in the CONNECT (Chronic TOtal OcclusioN CrossiNg with thE WildCat CatheTer) clinical trial.

14 Sep 2010

Study finds new therapeutic target for polycystic kidney disease

In work suggesting a new approach to treating polycystic kidney disease (PKD), a leading cause of kidney failure, researchers at Children's Hospital Boston were able to block the formation of fluid-filled cysts, the hallmark of the disease, in a mouse model. Their findings, using a compound that inhibits a receptor known as c-Met, will be published in the September 13th online edition of the Journal of Clinical Investigation.

14 Sep 2010

Pharmacyclics reports $9.3 million increase in total revenue for 2010 fiscal year

Pharmacyclics, Inc. today reported financial results for its fiscal year and fourth quarter which ended June 30, 2010.

14 Sep 2010

Myopia and Glaucoma genes identified

In global studies of more than 40,000 people from countries around the world, including Australia, researchers have found the genes responsible for two of the most common eye disorders - short-sightedness or myopia and glaucoma. The scientists believe this could open new diagnostic and management options.

13 Sep 2010

AstraZeneca, UCL collaborate to identify new therapeutic tools to modulate regenerative capacity of stem cells

AstraZeneca and UCL (University College London) today announced that they have entered into a collaboration to develop regenerative medicines for diabetic retinopathy (DR).

13 Sep 2010

Medtronic launches CareLink Network for Heart Failure

Medtronic, Inc. today introduced the CareLink® Network for Heart Failure, an extension of the world's largest remote implantable cardiac device monitoring system, that will be available this fall for heart failure clinicians.

13 Sep 2010

Study finds antibiotic safe for treatment of stroke and good companion therapy for tPA

An antibiotic appears to be a safe treatment for stroke and a good companion therapy for tPA, the clot buster that is currently the only FDA-approved drug therapy, researchers report.

13 Sep 2010

Kadlec integrates Medi-Span clinical decision support system with Epic EMR

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Kadlec Regional Medical Center will deploy Medi-Span® to provide clinicians with point-of-care access to comprehensive drug information and medication decision support via the facility's EMR system.

13 Sep 2010

North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer

CEL-SCI Corporation announced today it has received approval from the North Mississippi Health Services Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.

13 Sep 2010

Defibtech receives Health Canada approval for Lifeline View AED device

Defibtech, LLC, a leading innovator in the Automated External Defibrillation (AED) market, today announced that it has received approval from Health Canada to market the Lifeline View™ AED device. The Lifeline View AED is the first and only AED to offer a full-color interactive display that shows users step-by-step how to perform CPR and external defibrillation.

13 Sep 2010

Synta expands STA-9090 Phase 2 clinical trial in NSCLC

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it was expanding its Phase 2 clinical trial of STA-9090 in patients with Stage IIIB and Stage IV non-small cell lung cancer (NSCLC) from up to 69 patients to up to 146 patients based on encouraging activity observed in the first stage of the two stage clinical trial.

13 Sep 2010

Tetraphase Pharmaceuticals presents TP-434 drug candidate clinical data

Tetraphase Pharmaceuticals, Inc., yesterday presented new clinical and preclinical data for its lead drug candidate, TP-434, which demonstrated the novel antibiotic as a once daily intravenous (I.V.) monotherapy capable of treating multidrug-resistant gram-negative pathogens while also having potency and broad spectrum coverage of other serious and multidrug resistant gram-positive pathogens.

13 Sep 2010

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

Incyte Corporation announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) for the design of a pivotal Phase III trial for its JAK1 and JAK2 inhibitor, INCB18424 in patients with polycythemia vera (PV), a blood cancer that belongs to a group of diseases known as myeloproliferative neoplasms (MPNs).

13 Sep 2010

ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia

ARIAD Pharmaceuticals, Inc. today announced the initiation of the pivotal Phase 2 clinical trial of its investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL).

13 Sep 2010

XenoPort intends to initiate Phase 3 XP19986 trial for multiple sclerosis

XenoPort, Inc. announced today that it plans to move arbaclofen placarbil (AP), also known as XP19986, into Phase 3 development as a potential treatment of spasticity in multiple sclerosis (MS) patients.

13 Sep 2010

Heart Failure Society of America's 14th Annual Scientific Meeting convenes September 12, 2010

The Heart Failure Society of America (HFSA) 14th Annual Scientific Meeting convened Sunday, September 12, 2010 at the San Diego Convention Center in San Diego. This four-day meeting -- a forum for heart failure specialists to present research findings and advances in treatment -- will address emerging trends in research and new developments in the approach to treating patients with all stages of heart failure.

13 Sep 2010

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Vical Incorporated announced today the achievement of key efficacy, immunogenicity and safety results in a Phase 2 trial, establishing its TransVax™ cytomegalovirus (CMV) vaccine as the first to provide evidence of protection in immunocompromised hematopoietic cell transplant (HCT) recipients, and defining a potential pathway for further development.

13 Sep 2010

Athersys signs agreement with RTI Biologics for MAPC technology access

RTI Biologics Inc., a leading provider of orthopedic and other biologic implants, and Athersys Inc. a leader in regenerative medicine and cell therapy research and development, announced today an agreement under which Athersys will provide RTI access to its Multipotent Adult Progenitor Cell (MAPC) technologies.

13 Sep 2010

Therapy News and Research

AskBio enters patent license agreement with Pfizer for HCV therapy

Repetitive transcranial magnetic stimulation helps to regain motor function in partially paralyzed patients

St. John Hospital commences enrollment in CONNECT trial for peripheral artery disease

Study finds new therapeutic target for polycystic kidney disease

Pharmacyclics reports $9.3 million increase in total revenue for 2010 fiscal year

Myopia and Glaucoma genes identified

AstraZeneca, UCL collaborate to identify new therapeutic tools to modulate regenerative capacity of stem cells

Medtronic launches CareLink Network for Heart Failure

Study finds antibiotic safe for treatment of stroke and good companion therapy for tPA

Kadlec integrates Medi-Span clinical decision support system with Epic EMR

North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer

Defibtech receives Health Canada approval for Lifeline View AED device

Synta expands STA-9090 Phase 2 clinical trial in NSCLC

Tetraphase Pharmaceuticals presents TP-434 drug candidate clinical data

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia

XenoPort intends to initiate Phase 3 XP19986 trial for multiple sclerosis

Heart Failure Society of America's 14th Annual Scientific Meeting convenes September 12, 2010

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Athersys signs agreement with RTI Biologics for MAPC technology access

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News